News

Vinay Prasad, in surprise reversal, to rejoin FDA after abrupt departure

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

Precigen shares jump after US FDA approves first therapy for rare respiratory disease

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...
Fierce Pharma15d

Vinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than three months ago.
MedPage Today2d

Soap Recall Over Sepsis Risk; FDA Rehires Vinay Prasad; NIH Reports Patient to ICE

DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...
BioSpace2d

Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...
STAT4d

That was fast: Vinay Prasad is back at CBER

Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay ...

FDA Rehires Controversial Biologics Chief Just Days After Trump Fired Him

Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...